These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Dose escalation studies with caspofungin against Candida glabrata. Domán M; Kovács R; Perlin DS; Kardos G; Gesztelyi R; Juhász B; Bozó A; Majoros L J Med Microbiol; 2015 Sep; 64(9):998-1007. PubMed ID: 26296340 [TBL] [Abstract][Full Text] [Related]
5. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Wiederhold NP; Najvar LK; Bocanegra R; Molina D; Olivo M; Graybill JR Antimicrob Agents Chemother; 2007 May; 51(5):1616-20. PubMed ID: 17307976 [TBL] [Abstract][Full Text] [Related]
6. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Cota J; Carden M; Graybill JR; Najvar LK; Burgess DS; Wiederhold NP Antimicrob Agents Chemother; 2006 Nov; 50(11):3926-8. PubMed ID: 16940061 [TBL] [Abstract][Full Text] [Related]
7. Anticandidal effects of voriconazole and caspofungin, singly and in combination, against Candida glabrata, extracellularly and intracellularly in granulocyte-macrophage colony stimulating factor (GM-CSF)-activated human monocytes. Baltch AL; Bopp LH; Smith RP; Ritz WJ; Michelsen PB J Antimicrob Chemother; 2008 Dec; 62(6):1285-90. PubMed ID: 18772160 [TBL] [Abstract][Full Text] [Related]
8. Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. Spreghini E; Maida CM; Milici ME; Scalise G; Barchiesi F Antimicrob Agents Chemother; 2008 Feb; 52(2):513-7. PubMed ID: 18056279 [TBL] [Abstract][Full Text] [Related]
9. Candida glabrata and FKS mutations: witnessing the emergence of the true multidrug-resistant Candida. Ostrosky-Zeichner L Clin Infect Dis; 2013 Jun; 56(12):1733-4. PubMed ID: 23487384 [No Abstract] [Full Text] [Related]
10. Synergy of caspofungin with human polymorphonuclear granulocytes for killing Candida albicans. Tullio V; Mandras N; Scalas D; Allizond V; Banche G; Roana J; Greco D; Castagno F; Cuffini AM; Carlone NA Antimicrob Agents Chemother; 2010 Sep; 54(9):3964-6. PubMed ID: 20585121 [TBL] [Abstract][Full Text] [Related]
11. Candida and candidaemia. Susceptibility and epidemiology. Arendrup MC Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246 [TBL] [Abstract][Full Text] [Related]
12. Combination of caspofungin or anidulafungin with antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro. Harris MR; Coote PJ Int J Antimicrob Agents; 2010 Apr; 35(4):347-56. PubMed ID: 20106636 [TBL] [Abstract][Full Text] [Related]
14. The echinocandin caspofungin impairs the innate immune mechanism against Candida parapsilosis. van Asbeck EC; Hoepelman AI; Scharringa J; Verhoef J Int J Antimicrob Agents; 2009 Jan; 33(1):21-6. PubMed ID: 18774697 [TBL] [Abstract][Full Text] [Related]
15. Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin. Cota JM; Grabinski JL; Talbert RL; Burgess DS; Rogers PD; Edlind TD; Wiederhold NP Antimicrob Agents Chemother; 2008 Mar; 52(3):1144-6. PubMed ID: 18086838 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the "Dip Effect" Phenomenon in Antifungal Susceptibility Testing of Candida spp. against Echinocandins by Use of Gradient Concentration Strips. Siopi M; Tsala M; Siafakas N; Zerva L; Meletiadis J J Clin Microbiol; 2015 Nov; 53(11):3654-9. PubMed ID: 26338855 [TBL] [Abstract][Full Text] [Related]
17. Caspofungin activity against clinical isolates of azole cross-resistant Candida glabrata overexpressing efflux pump genes. Posteraro B; Sanguinetti M; Fiori B; La Sorda M; Spanu T; Sanglard D; Fadda G J Antimicrob Chemother; 2006 Aug; 58(2):458-61. PubMed ID: 16757500 [TBL] [Abstract][Full Text] [Related]
18. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata. Oliveira ER; Fothergill AW; Kirkpatrick WR; Coco BJ; Patterson TF; Redding SW Antimicrob Agents Chemother; 2005 Aug; 49(8):3544-5. PubMed ID: 16048980 [TBL] [Abstract][Full Text] [Related]
19. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates. Beyda ND; Liao G; Endres BT; Lewis RE; Garey KW Antimicrob Agents Chemother; 2015 Sep; 59(9):5405-12. PubMed ID: 26100700 [TBL] [Abstract][Full Text] [Related]
20. Post-antifungal effects and time-kill studies of anidulafungin, caspofungin, and micafungin against Candida glabrata and Candida parapsilosis. Smith RP; Baltch A; Bopp LH; Ritz WJ; Michelsen PP Diagn Microbiol Infect Dis; 2011 Oct; 71(2):131-8. PubMed ID: 21865002 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]